These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31181961)

  • 41. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
    Freiman JM; Jacobson KR; Muyindike WR; Horsburgh CR; Ellner JJ; Hahn JA; Linas BP
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):405-412. PubMed ID: 29239900
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isoniazid preventive therapy completion and factors associated with non-completion among patients on antiretroviral therapy at Kisenyi Health Centre IV, Kampala, Uganda.
    Amanya I; Muhoozi M; Aruhomukama D; Ssebagereka A; Mugambe R
    PLoS One; 2023; 18(8):e0277739. PubMed ID: 37607176
    [TBL] [Abstract][Full Text] [Related]  

  • 43.
    Lai J; Dememew Z; Jerene D; Abashawl A; Feleke B; Teklu AM; Ruff A
    Int J Tuberc Lung Dis; 2019 Mar; 23(3):371-377. PubMed ID: 30871669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy.
    Sumner T; Houben RM; Rangaka MX; Maartens G; Boulle A; Wilkinson RJ; White RG
    AIDS; 2016 May; 30(8):1279-86. PubMed ID: 26950316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.
    Ayele HT; van Mourik MS; Bonten MJ
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1342-1347. PubMed ID: 27725045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
    Nabity SA; Gunde LJ; Surie D; Shiraishi RW; Kirking HL; Maida A; Auld AF; Odo M; Jahn A; Nyirenda RK; Oeltmann JE
    PLoS One; 2021; 16(4):e0248115. PubMed ID: 33793577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
    Costenaro P; Massavon W; Lundin R; Nabachwa SM; Fregonese F; Morelli E; Alowo A; Nannyonga Musoke M; Namisi CP; Kizito S; Bilardi D; Mazza A; Cotton MF; Giaquinto C; Penazzato M
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):e1-8. PubMed ID: 26761275
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mid-level managers' perspectives on implementing isoniazid preventive therapy for people living with HIV in Ugandan health districts: a qualitative study.
    Christian C; Kakande E; Nahurira V; Akatukwasa C; Atwine F; Bakanoma R; Itiakorit H; Owaraganise A; DiIeso W; Rast D; Kabami J; Peretz JJ; Shade SB; Kamya MR; Havlir DV; Chamie G; Camlin CS
    BMC Health Serv Res; 2024 Mar; 24(1):313. PubMed ID: 38454501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda.
    Shapiro AE; van Heerden A; Schaafsma TT; Hughes JP; Baeten JM; van Rooyen H; Tumwesigye E; Celum CL; Barnabas RV
    J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29381257
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
    Chamie G; Hahn JA; Kekibiina A; Emenyonu NI; Beesiga B; Marson K; Fatch R; Lodi S; Adong J; Thirumurthy H; McDonell MG; Gandhi M; Bryant K; Havlir DV; Kamya MR; Muyindike WR
    Lancet Glob Health; 2023 Dec; 11(12):e1899-e1910. PubMed ID: 37973340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.
    Dowdy DW; Golub JE; Saraceni V; Moulton LH; Cavalcante SC; Cohn S; Pacheco AG; Chaisson RE; Durovni B
    J Acquir Immune Defic Syndr; 2014 Aug; 66(5):552-8. PubMed ID: 24853308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.
    Mills HL; Cohen T; Colijn C
    J R Soc Interface; 2011 Oct; 8(63):1510-20. PubMed ID: 21508012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health system challenges: An obstacle to the success of isoniazid preventive therapy.
    Okoli EI; Roets L
    S Afr Med J; 2016 Nov; 106(11):1079-1081. PubMed ID: 27842624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
    Cowger TL; Thai LH; Duong BD; Danyuttapolchai J; Kittimunkong S; Nhung NV; Nhan DT; Monkongdee P; Thoa CK; Khanh VT; Nateniyom S; Yen NTB; Ngoc DV; Thinh T; Whitehead S; Pevzner ES
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):512-521. PubMed ID: 29023251
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A mid-level health manager intervention to promote uptake of isoniazid preventive therapy among people with HIV in Uganda: a cluster randomised trial.
    Kakande E; Christian C; Balzer LB; Owaraganise A; Nugent JR; DiIeso W; Rast D; Kabami J; Johnson Peretz J; Camlin CS; Shade SB; Geng EH; Kwarisiima D; Kamya MR; Havlir DV; Chamie G
    Lancet HIV; 2022 Sep; 9(9):e607-e616. PubMed ID: 35908553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
    Semitala FC; Kadota JL; Musinguzi A; Nabunje J; Welishe F; Nakitende A; Akello L; Bishop O; Patel D; Sammann A; Nahid P; Belknap R; Kamya MR; Handley MA; Phillips PPJ; Katahoire A; Berger CA; Kiwanuka N; Katamba A; Dowdy DW; Cattamanchi A
    PLoS Med; 2021 Dec; 18(12):e1003875. PubMed ID: 34914696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV.
    Valinetz ED; Matemo D; Gersh JK; Joudeh LL; Mendelsohn SC; Scriba TJ; Hatherill M; Kinuthia J; Wald A; Cangelosi GA; Barnabas RV; Hawn TR; Horne DJ
    AIDS; 2022 Aug; 36(10):1363-1371. PubMed ID: 35608118
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
    Maokola W; Ngowi B; Lawson L; Robert M; Mahande M; Todd J; Msuya S
    Int J Infect Dis; 2021 Feb; 103():562-567. PubMed ID: 33276111
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors associated with isoniazid preventive treatment interruption and completion among PLHIV in Gombe Hospital, Uganda, 2017-2019.
    Ssendikwanawa E; Juniour Nsubuga E; Lee S; Frances Zalwango J; Joan Bayowa R; Judith Ssemasaazi A; Ronald Muganga K; Adolphus C; Akunzirwe R; Nante Wangi R; Ronald Kasoma M; Kalyango JN; Karamagi C; Sekaggya-Wiltshire C
    J Clin Tuberc Other Mycobact Dis; 2023 May; 31():100349. PubMed ID: 37181458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.